rafaelnlins / Shutterstock.com
13 September 2024NewsBiotechnologySarah Speight

Sanofi signs global rights deal to develop rare cancer therapy

Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 July 2024   Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.
Europe
27 June 2024   In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More on this story

Americas
30 July 2024   Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.
Europe
27 June 2024   In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More on this story

Americas
30 July 2024   Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.
Europe
27 June 2024   In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.